Prognosis
Warp Speed Head Says J&J, Astra Trials May Restart This Week
- Slaoui says he understands the Astra trial change ‘imminent’
- Both companies using viral vector based on adenoviruses
Photographer: Mikael Sjoberg/Bloomberg
This article is for subscribers only.
Moncef Slaoui, the head of Operation Warp Speed, said he expects the U.S. trials of vaccines made by AstraZeneca Plc and Johnson & Johnson to restart as soon as this week.
The two companies developing Covid-19 vaccines backed by Operation Warp Speed temporarily halted their trials because participants fell ill, slowing down the race for a shot to halt the pandemic. J&J paused its trial last week when a participant got sick. AstraZeneca’s trial paused last month after a woman in the U.K. study developed neurological symptoms and the U.S. Food & Drug Administration has yet to clear the study to resume in the U.S.